ReviewPharmaceutical research2010
Mucosal vaccines: recent progress in understanding the natural barriers.
Review in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Recent Advancements in Non-Invasive Vaccination Strategies.Vaccines · 2025Review
- A Review of Non-Invasive Drug Delivery through Respiratory Routes.Pharmaceutics · 2022Review
- Article
- Role of Interleukin-6 in the Antigen-Specific Mucosal Immunoglobulin A Responses Induced by CpG Oligodeoxynucleotide-Loaded Cationic Liposomes.Membranes · 2022Article
- Can the Nasal Cavity Help Tackle COVID-19?Pharmaceutics · 2021Review
- An update on oral drug deliveryActa pharmaceutica Sinica. B · 2021Review
- Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?International journal of pharmaceutics · 2021Review
- Polymeric Caffeic Acid Acts as a Nasal Vaccine Formulation againstPharmaceutics · 2021Article
- Article
- Evaluation of Intranasal Vaccine Delivery Using Anatomical Replicas of Infant Nasal Airways.Pharmaceutical research · 2021Article
- mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.Frontiers in immunology · 2021Review
- Essential Role of Host Double-Stranded DNA Released from Dying Cells by Cationic Liposomes for Mucosal Adjuvanticity.Vaccines · 2019Article
- Attachment of class B CpG ODN onto DOTAP/DC-chol liposome in nasal vaccine formulations augments antigen-specific immune responses in mice.BMC research notes · 2017Article
- Current prospects and future challenges for nasal vaccine delivery.Human vaccines & immunotherapeutics · 2017Review
- Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.Clinical immunology (Orlando, Fla.) · 2015Article
- Controlled analysis of nanoparticle charge on mucosal and systemic antibody responses following pulmonary immunization.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Article
- Synthesis, characterization, and immune efficacy of layered double hydroxide@SiO2 nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine.International journal of nanomedicine · 2015Article
- Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.Future microbiology · 2012Review
- Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination.Immune network · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has long been known that protection against pathogens invading the organism via mucosal surfaces correlates better with the presence of specific antibodies in local secretions than with serum antibodies. The most effective way to induce mucosal immunity is to administer antigens directly to the mucosal surface. The development of vaccines for mucosal application requires antigen delivery systems and immunopotentiators that efficiently facilitate the presentation of the antigen to the mucosal immune system. This review provides an overview of the events within mucosal tissues that lead to protective mucosal immune responses. The understanding of those biological mechanisms, together with knowledge of the technology of vaccines and adjuvants, provides guidance on important technical aspects of mucosal vaccine design. Not being exhaustive, this review also provides information related to modern adjuvants, including polymeric delivery systems and immunopotentiators.
Indexed as
Identifiers
19953309What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.